Fig. 1 · Structure

Documents & Downloads

Nanchangmycin

Cat. No. A10621 CAS 65101-87-3
Nanchangmycin (dianemycin) is a polyether antibiotic with similar structure to dianemycin and is very active against a broad spectrum of harmful nematodes and insects but not for for mammals and plants.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
JEG-3 CC50 6.1 μM Cytotoxicity against human JEG3 cells incubated for 36 hrs by resazurin-dye based Alamar blue assay [PMID: 31549836]

Nanchangmycin Research Summary

This section summarizes 4 in vitro studies of Nanchangmycin from 3 published references. In vitro models include MDCK cells; A549 cells.

Nanchangmycin In Vitro Studies

In MDCK multicycle growth assays, Nanchangmycin at 1 μM produced an approximately 100- fold decrease in viral production compared with media alone. In A549 cells, Nanchangmycin inhibited rubella virus infection with a half-maximal inhibitory concentration of 0.03 µM, normalized to DMSO vehicle control. In pretreated U2OS cells, Nanchangmycin blocked transferrin-conjugated bead internalization equivalently to dynasore. In MDCK cells exposed to oseltamivir-resistant influenza A virus, survival with Nanchangmycin reached 50% in comparison with oseltamivir carboxylate or DMSO. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced viral production in MDCK cells

Cell-based study · MDCK cells [1]

In MDCK cells, Nanchangmycin at 1 μM produced an approximately 100- fold decrease in viral production compared with media alone in multicycle growth assays.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infectious viral particles were titered via TCID 50 assayviral production approximately 100- fold decrease in viral production[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
6–72 h
Method
with media alone or with the nanchangmycin
Co-treatment
Other interventions in this design: H1N1 MOI of 0.01. Compound effect isolated by the comparison: media alone or with the nanchangmycin.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Nanchangmycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Viral titer reduction assay (S21, S22, S23); Results > Screening for inhibitors of IAV infection via the HA assay (S90)

infectious viral particles were titered via TCID 50 assay: infectious viral particles were titered via TCID 50 assay; comparator: media alone — Materials and Methods > Viral titer reduction assay (S23); Results > Screening for inhibitors of IAV infection via the HA assay (S90)

Inhibition of rubella virus infection in A549 cells

Cell-based study · A549 cells [2]

In A549 cells treated with Nanchangmycin, rubella virus infection was inhibited with a half-maximal inhibitory concentration of 0.03 µM, normalized to the DMSO vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percent infectionIC50 IC50) of 0.03 µM[2]

Literature-Reported Treatment Conditions

Exposure duration
48 hpi
Method
treated with indicated concentrations of nanchangmycin
Vehicle
DMSO
Co-treatment
Other interventions in this design: rubella RA27/3 virus MOI = 0.2. Compound effect isolated by the comparison: normalized to vehicle control (DMSO).
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Nanchangmycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > High-throughput screen for antivirals against rubella virus (S6); Materials and methods > High-throughput screen (S88, S98); Materials and methods > Dose–responses (S101, S104); Fig. 1. legend (S132, S133, S134)

percent infection: percent infection; comparator: vehicle control (DMSO) — Results > High-throughput screen for antivirals against rubella virus (S6); Fig. 1. legend (S134)

Blockade of transferrin-conjugated bead uptake in U2OS cells

Cell-based study · U2OS cells [3]

U2OS cells were pretreated with Nanchangmycin before exposure to transferrin-conjugated beads. Nanchangmycin blocked bead internalization equivalently to dynasore.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of transferrin-conjugated bead uptake (Mander’s colocalization analysis)Reported result both nocodazole and nanchangmycin block this internalization equivalently to dynasore[3]

Literature-Reported Treatment Conditions

Exposure duration
pretreated with the indicated drug for 45 min and subsequently treated with transferrin-conjugated beads for 45 min
Method
pretreated
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Nanchangmycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Flaviviral Uptake and Large-Cargo Internalization Are Dependent upon Microtubules. (S63); Fig. 4. legend (S113, S116)

Quantification of transferrin-conjugated bead uptake (Mander’s colocalization analysis): Quantification of transferrin-conjugated bead uptake (Mander’s colocalization analysis); comparator: dynasore, an inhibitor of dynamin — Results > Flaviviral Uptake and Large-Cargo Internalization Are Dependent upon Microtubules. (S63); Fig. 4. legend (S116)

Cell survival during oseltamivir-resistant influenza A virus exposure

Cell-based study · MDCK cells [1]

In MDCK cells exposed to oseltamivir-resistant influenza A virus, survival with Nanchangmycin reached 50% in comparison with oseltamivir carboxylate or DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survival rate of MDCK cellssurvival rate 50%[1]

Literature-Reported Treatment Conditions

Method
in the presence of nanchangmycin
Co-treatment
Other interventions in this design: Influenza A virus (oseltamivir-resistant) MOI of 1. Compound effect isolated by the comparison: Compared with oseltamivir carboxylate or DMSO.
Reported limits
Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Nanchangmycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Oseltamivir-resistant influenza virus sensitivity assay (S41); Results > Oseltamivir-resistant influenza virus is sensitive to nanchangmycin, which has broad-spectrum antiviral activity (S143)

survival rate of MDCK cells: survival rate of MDCK cells; comparator: oseltamivir carboxylate or DMSO — Results > Oseltamivir-resistant influenza virus is sensitive to nanchangmycin, which has broad-spectrum antiviral activity (S143)

Specifications

Manufacturer Adooq Bioscience
CAS Number 65101-87-3
Formula C47H77NaO14
Molecular Weight 889.1
SMILES
C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@]3(O2)[C@@H]([C@H](C[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)/C=C(\C)/C(=O)[C@H](C)C[C@H](C)C(=O)[O-])C)O)C)O[C@@H]6CC[C@@H]([C@H](O6)C)OC)C)C)(CO)O)C.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (104.6 mM)
Water Insoluble
Ethanol 93 mg/mL (104.6 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Nanchangmycin Research References

  1. [1] Zhang H, Liu C, Cai S, et al. Nanchangmycin suppresses influenza A virus infection by blocking endosomal acidification. Acta Biochim Biophys Sin (Shanghai) (2025). PMID: 40746183 DOI: 10.3724/abbs.2025102 Source material
  2. [2] Dittmar M, Whig K, Miller J, et al. Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus. PNAS Nexus (2023). PMID: 37674858 DOI: 10.1093/pnasnexus/pgad256 Source material
  3. [3] Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent endocytic pathway. Proc Natl Acad Sci U S A (2018). PMID: 29610346 DOI: 10.1073/pnas.1720032115 Source material

Added to your cart

View Cart Checkout
Loading...